NCT04972110: Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior therapy of an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor; Patients with uncontrolled, symptomatic brain metastases

Comments are closed.

Up ↑